Zyx citron and Soolantra cream

This image features two distinct pharmaceutical products. The first is Zyx citron, an anti-inflammatory throat lozenge containing benzydamine hydrochloride. The brand Zyx is currently marketed by Viatris, a global healthcare company formed in 2020 through the merger of Mylan and Pfizer's Upjohn division. Manufacturing for Viatris products occurs across a vast global network, with European distribution often handled by regional branches.

The second product is Soolantra (ivermectin) cream, a prescription medication used to treat rosacea. Soolantra is a brand property of Galderma, a leading dermatology company headquartered in Switzerland. Galderma was originally founded as a joint venture between Nestlé and L'Oréal in 1981 but became an independent entity in 2019 after being acquired by an investment consortium led by EQT Partners. Its products are manufactured in specialized derma-production facilities globally, including major sites in France and North America.